The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kummer, M.
Right arrow Articles by Biedermann, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kummer, M.
Right arrow Articles by Biedermann, B. C.
The Journal of Immunology, 2005, 174: 1947-1953.
Copyright © 2005 by The American Association of Immunologists

Vascular Endothelial Cells Have Impaired Capacity to Present Immunodominant, Antigenic Peptides: A Mechanism of Cell Type-Specific Immune Escape1

Marco Kummer*,{dagger}, Avital Lev{ddagger}, Yoram Reiter{ddagger} and Barbara C. Biedermann2,*,{dagger}

* Department of Medicine, University Hospital Bruderholz, Bruderholz, Switzerland; {dagger} Department of Research, University Hospital Basel, Basel, Switzerland; and {ddagger} Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel

Vascular endothelial cells (EC) are an exposed target tissue in the course of CTL-mediated alloimmune diseases such as graft-vs-host disease (GVHD) or solid organ transplant rejection. The outcome of an interaction between CTL and target cells is determined by the amount of Ag presented and the costimulatory signals delivered by the target cells. We compared human EC with leukocytes and epithelial cells as targets for peptide-specific, MHC class I-restricted CTL clones. EC were poor targets for immunodominant CTL. Both endogenously processed antigenic proteins and exogenously added antigenic peptides are presented at 50- to 5000-fold lower levels on EC compared with any other target cell analyzed. This quantitative difference fully explained the poor CTL-mediated killing of EC. There was no evidence that lack of costimulation would contribute significantly to this cell type-specific difference in CTL activation. An HLA-A2-specific CTL clone that killed a broad selection of HLA A2-positive target cells equally well, killed EC less efficiently. Our data suggest that EC present a different Ag repertoire compared with other cell types. By this mechanism, these cells may escape an attack by effector CTL, which have been educated by professional APCs and are specific for immunodominant antigenic peptides.




This article has been cited by other articles:


Home page
BloodHome page
B. Bolinger, P. Krebs, Y. Tian, D. Engeler, E. Scandella, S. Miller, D. C. Palmer, N. P. Restifo, P.-A. Clavien, and B. Ludewig
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen
Blood, May 1, 2008; 111(9): 4588 - 4595.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Doebis, S. Schu, J. Ladhoff, A. Busch, F. Beyer, J. Reiser, R. F. Nicosia, S. Broesel, H.-D. Volk, and M. Seifert
An anti-major histocompatibility complex class I intrabody protects endothelial cells from an attack by immune mediators
Cardiovasc Res, November 1, 2006; 72(2): 331 - 338.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.